HomeProductsBioactive CompoundsEpigeneticsHDACIvaltinostat
Chemical structure of CAS 936221-33-9

Ivaltinostat

CAS No.936221-33-9
MDL No.MFCD25976805
MFC24H33N3O4
MW427.50
InChI KeyAUGCSOFQTDKPSO-RGVLZGJSSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.936221-33-9
Product NameIvaltinostat

Associated Conditions

neoplasm·pancreatic neoplasm·myelodysplastic syndrome
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.

Scientific reports • Vol. 8, Issue 1 • 2018
PMID: 30068917PMC: PMC6070546DOI: 10.1038/s41598-018-30008-5

CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.

Scientific reports • Vol. 7, Issue 1 • 2017
PMID: 28883618PMC: PMC5589721DOI: 10.1038/s41598-017-11094-3

Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology • Vol. 20, Issue 5 • 2016
PMID: 27610034PMC: PMC5014994DOI: 10.4196/kjpp.2016.20.5.477

Documentation